NPHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NPHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nutra Pharma's Book Value per Share for the quarter that ended in Sep. 2022 was $-0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Nutra Pharma (OTCPK:NPHC) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of Nutra Pharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Rik J Deitsch | officer: Chief Executive Officer | 4001 NW 73 WAY, CORAL SPRINGS FL 33065 |
Dan Oran | director | 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351 |
Bruno Sartori | other: Former CFO | 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308 |
Harold Henry Rumph | director, officer: President - ReceptoPharm | 1537 N.W. 65TH AVENUE, PLANTATION FL 33313 |
David Michael Isserman | officer: Chief Marketing Officer | 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065 |
Garry Pottruck | director | 10768 NW 18TH CT, CORAL SPRINGS FL 33071 |
Paul F Reid | director | 9610 NW 24 CT, SUNRISE FL 33322 |
Michael Doherty | director, officer: Executive Chairman | |
Tanvir A Khandaker | director | 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016 |
Stewart Alan Lonky | director | 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272 |
Stanley Jack Cherelstein | director | 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990 |
Michael Flax | director, officer: Chief Financial Officer | 2499 BANYAN RD, BOCA RATON FL 33432 |
Mcclelland David C Sr | director | P.O. BOX 263, FINDLEY LAKE NY 14736 |
Mitchell S Felder | director | PO BOX 1332, HERMITAGE PA 16148 |
Khalsa Soram Singh Md | director | 436 N BEDFORD DR, BEVERLY HILLS CA 90210 |
From GuruFocus
By Marketwired Marketwired • 04-19-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.